Prostate tumor cell exosomes containing hyaluronidase Hyal1 stimulate prostate stromal cell motility by engagement of FAK-mediated integrin signaling.


Journal

Matrix biology : journal of the International Society for Matrix Biology
ISSN: 1569-1802
Titre abrégé: Matrix Biol
Pays: Netherlands
ID NLM: 9432592

Informations de publication

Date de publication:
05 2019
Historique:
received: 14 12 2017
revised: 28 03 2018
accepted: 08 05 2018
pubmed: 14 5 2018
medline: 31 8 2019
entrez: 14 5 2018
Statut: ppublish

Résumé

The hyaluronidase Hyal1 is clinically and functionally implicated in prostate cancer progression and metastasis. Elevated Hyal1 accelerates vesicular trafficking in prostate tumor cells, thereby enhancing their metastatic potential in an autocrine manner through increased motility and proliferation. In this report, we found Hyal1 protein is a component of exosomes produced by prostate tumor cell lines overexpressing Hyal1. We investigated the role of exosomally shed Hyal1 in modulating tumor cell autonomous functions and in modifying the behavior of prostate stromal cells. Catalytic activity of Hyal1 was necessary for enrichment of Hyal1 in the exosome fraction, which was associated with increased presence of LC3BII, an autophagic marker, in the exosomes. Hyal1-positive exosome contents were internalized from the culture medium by WPMY-1 prostate stromal fibroblasts. Treatment of prostate stromal cells with tumor exosomes did not affect proliferation, but robustly stimulated their migration in a manner dependent on Hyal1 catalytic activity. Increased motility of exosome-treated stromal cells was accompanied by enhanced adhesion to a type IV collagen matrix, as well as increased FAK phosphorylation and integrin engagement through dynamic membrane residence of β1 integrins. The presence of Hyal1 in tumor-derived exosomes and its ability to impact the behavior of stromal cells suggests cell-cell communication via exosomes is a novel mechanism by which elevated Hyal1 promotes prostate cancer progression.

Identifiants

pubmed: 29753676
pii: S0945-053X(17)30464-X
doi: 10.1016/j.matbio.2018.05.002
pmc: PMC6230312
mid: NIHMS969071
pii:
doi:

Substances chimiques

Integrins 0
MAP1LC3B protein, human 0
Microtubule-Associated Proteins 0
Focal Adhesion Kinase 1 EC 2.7.10.2
PTK2 protein, human EC 2.7.10.2
HYAL1 protein, human EC 3.2.1.35
Hyaluronoglucosaminidase EC 3.2.1.35

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

165-179

Subventions

Organisme : NIGMS NIH HHS
ID : P20 GM104320
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA086862
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA165574
Pays : United States

Informations de copyright

Copyright © 2018 International Society of Matrix Biology. Published by Elsevier B.V. All rights reserved.

Références

J Urol. 2002 May;167(5):2037-41
pubmed: 11956433
Traffic. 2002 May;3(5):321-30
pubmed: 11967126
Glycobiology. 2002 Mar;12(3):37R-42R
pubmed: 11971857
Clin Cancer Res. 2002 Sep;8(9):2912-23
pubmed: 12231536
Urol Int. 2002;69(4):266-72
pubmed: 12444281
Cancer Res. 2003 May 15;63(10):2638-44
pubmed: 12750291
Mol Hum Reprod. 2004 Feb;10(2):91-7
pubmed: 14742693
Nat Rev Cancer. 2004 Jul;4(7):528-39
pubmed: 15229478
Cancer Res. 2005 Sep 1;65(17):7782-9
pubmed: 16140946
Am J Pathol. 2006 Oct;169(4):1415-26
pubmed: 17003496
J Immunol. 2007 Dec 15;179(12):8191-9
pubmed: 18056362
Science. 2008 Feb 29;319(5867):1244-7
pubmed: 18309083
Front Biosci. 2008 May 01;13:5664-80
pubmed: 18508614
Gynecol Oncol. 2008 Jul;110(1):13-21
pubmed: 18589210
J Biol Chem. 2009 Apr 3;284(14):9433-42
pubmed: 19201751
Am J Pathol. 2009 Mar;174(3):1027-36
pubmed: 19218337
FEBS Lett. 2009 Apr 17;583(8):1337-43
pubmed: 19306879
PLoS One. 2009;4(4):e5219
pubmed: 19381331
Biochem Soc Trans. 2009 Oct;37(Pt 5):1072-6
pubmed: 19754454
Lab Invest. 2009 Nov;89(11):1317-28
pubmed: 19786948
Cancer Cell. 2010 Feb 17;17(2):135-47
pubmed: 20138012
Cancer Res. 2010 Dec 1;70(23):9621-30
pubmed: 21098712
Semin Cancer Biol. 2011 Apr;21(2):139-46
pubmed: 21251983
Exp Cell Res. 2011 May 1;317(8):1214-25
pubmed: 21315068
Cell. 2011 Jun 24;145(7):1012-22
pubmed: 21703446
Cold Spring Harb Perspect Biol. 2011 Sep 01;3(9):a005074
pubmed: 21885598
Nat Med. 2012 Jun;18(6):883-91
pubmed: 22635005
J Biol Chem. 2013 Apr 5;288(14):10093-9
pubmed: 23430739
J Mol Med (Berl). 2013 Apr;91(4):431-7
pubmed: 23519402
Nat Rev Cancer. 2013 Nov;13(11):813-20
pubmed: 24108097
Mol Carcinog. 2015 Jul;54(7):554-65
pubmed: 24347249
Oncogene. 2015 Jan 15;34(3):290-302
pubmed: 24441045
Adv Cancer Res. 2014;123:1-34
pubmed: 25081524
J Biol Chem. 2015 Feb 20;290(8):4545-51
pubmed: 25568317
Oncotarget. 2015 Feb 20;6(5):3280-91
pubmed: 25682864
Genomics Proteomics Bioinformatics. 2015 Feb;13(1):17-24
pubmed: 25724326
J Biol Chem. 2015 May 22;290(21):13144-56
pubmed: 25855794
Blood. 2015 Aug 27;126(9):1106-17
pubmed: 26100252
Biochem Biophys Res Commun. 2015 Sep 25;465(3):569-74
pubmed: 26284973
Sci Adv. 2015 Dec 18;1(11):e1500603
pubmed: 26824057
Oncotarget. 2016 Sep 13;7(37):59173-59188
pubmed: 27385095
Mol Cancer Res. 2016 Nov;14(11):1136-1146
pubmed: 27439335
Autophagy. 2016 Sep;12(9):1679-80
pubmed: 27439889
Autophagy. 2016 Oct 2;12(10):1685-1686
pubmed: 27483986
J Cell Sci. 2016 Oct 15;129(20):3685-3693
pubmed: 27672021
Oncotarget. 2016 Dec 27;7(52):86999-87015
pubmed: 27894104
Cell Mol Life Sci. 2018 Jan;75(2):193-208
pubmed: 28733901
Adv Exp Med Biol. 2017;998:3-19
pubmed: 28936729
Cancer Res. 2017 Dec 1;77(23):6480-6488
pubmed: 29162616
Front Cell Dev Biol. 2017 Nov 07;5:95
pubmed: 29164114
FEBS Lett. 1997 Nov 17;417(3):307-10
pubmed: 9409739
J Biol Chem. 1998 Aug 7;273(32):20121-7
pubmed: 9685355

Auteurs

Caitlin O McAtee (CO)

Department of Biochemistry, University of Nebraska, Lincoln, NE, United States.

Christine Booth (C)

Department of Biochemistry, University of Nebraska, Lincoln, NE, United States.

Christian Elowsky (C)

Morrison Microscopy Facility, University of Nebraska, Lincoln, NE, United States.

Lei Zhao (L)

Department of Molecular Physiology and Biophysics, Holden Comprehensive Cancer Center, University of Iowa Carver College of Medicine; Iowa City, IA, United States.

Jeremy Payne (J)

Department of Biochemistry, University of Nebraska, Lincoln, NE, United States.

Teresa Fangman (T)

Morrison Microscopy Facility, University of Nebraska, Lincoln, NE, United States.

Steve Caplan (S)

Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, United States; Fred and Pamela Buffett Cancer Center, Omaha, NE, United States.

Michael D Henry (MD)

Department of Molecular Physiology and Biophysics, Holden Comprehensive Cancer Center, University of Iowa Carver College of Medicine; Iowa City, IA, United States.

Melanie A Simpson (MA)

Department of Molecular and Structural Biochemistry, North Carolina State University, Raleigh, NC, United States. Electronic address: msimpso3@ncsu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH